12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Brostallicin: Interim Phase II data

Interim data from 47 evaluable patients with metastatic TNBC in an open-label, U.S. Phase II trial showed that brostallicin plus cisplatin led to a 3-month PFS rate of 51% and a 6-month PFS rate of 26%....

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >